# Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/DSGN/design-therapeutics-to-participate-in-2026-jefferies-global-healthcare-conference
Ticker: DSGN
Company: Design Therapeutics
Source: Design Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.designtx.com
## Summary

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global

## Article Body
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global
## Recent Company News
- 2026-06-30 12:00 EST — [Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1](https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-multiple-a-1d18e89a) — Source: Design Therapeutics
- 2026-06-25 13:46 EST — [Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/DSGN/design-therapeutics-to-participate-in-2026-jefferies-global-healthcare-conference) — Source: Design Therapeutics
- 2026-06-25 13:46 EST — [Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia](https://biopharmsignal.com/news/DSGN/design-therapeutics-announces-four-week-iv-data-from-the-restore-fa-trial-of-dt-216p2-demonstrating-clinical-improvements-and-comprehensive-biomarker-activity-in-friedreich-ataxia) — Source: Design Therapeutics
- 2026-06-25 13:46 EST — [Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026](https://biopharmsignal.com/news/DSGN/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreich-s-ataxia-on-monday-may-18-2026) — Source: Design Therapeutics
- 2026-06-25 13:46 EST — [Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/DSGN/design-therapeutics-to-participate-in-2025-jefferies-global-healthcare-conference) — Source: Design Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)